JP2019513394A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513394A5 JP2019513394A5 JP2018553980A JP2018553980A JP2019513394A5 JP 2019513394 A5 JP2019513394 A5 JP 2019513394A5 JP 2018553980 A JP2018553980 A JP 2018553980A JP 2018553980 A JP2018553980 A JP 2018553980A JP 2019513394 A5 JP2019513394 A5 JP 2019513394A5
- Authority
- JP
- Japan
- Prior art keywords
- acid sequence
- nucleic acid
- domain
- isolated
- callar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical group 0.000 claims description 83
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 82
- 108010054218 Factor VIII Proteins 0.000 claims description 44
- 102000001690 Factor VIII Human genes 0.000 claims description 44
- 229960000301 factor viii Drugs 0.000 claims description 44
- 239000012634 fragment Substances 0.000 claims description 29
- 230000000961 alloantigen Effects 0.000 claims description 27
- 108020003175 receptors Proteins 0.000 claims description 25
- 102000005962 receptors Human genes 0.000 claims description 25
- 210000004027 cell Anatomy 0.000 claims description 24
- 108010043610 KIR Receptors Proteins 0.000 claims description 23
- 150000001413 amino acids Chemical group 0.000 claims description 18
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 claims description 17
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 claims description 17
- 230000003834 intracellular effect Effects 0.000 claims description 16
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 15
- 230000011664 signaling Effects 0.000 claims description 15
- 102100026735 Coagulation factor VIII Human genes 0.000 claims description 14
- 208000031220 Hemophilia Diseases 0.000 claims description 14
- 208000009292 Hemophilia A Diseases 0.000 claims description 14
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 230000004068 intracellular signaling Effects 0.000 claims description 10
- 230000001086 cytosolic effect Effects 0.000 claims description 9
- 230000000139 costimulatory effect Effects 0.000 claims description 8
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 6
- 102000006306 Antigen Receptors Human genes 0.000 claims description 4
- 108010083359 Antigen Receptors Proteins 0.000 claims description 4
- 101000945339 Homo sapiens Killer cell immunoglobulin-like receptor 2DS2 Proteins 0.000 claims description 4
- 102100033630 Killer cell immunoglobulin-like receptor 2DS2 Human genes 0.000 claims description 4
- 230000031146 intracellular signal transduction Effects 0.000 claims description 4
- 241000713666 Lentivirus Species 0.000 claims description 2
- 210000004405 cytokine-induced killer cell Anatomy 0.000 claims description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 2
- 239000012636 effector Substances 0.000 claims description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 2
- 210000001616 monocyte Anatomy 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
- 210000003289 regulatory T cell Anatomy 0.000 claims description 2
- 231100000419 toxicity Toxicity 0.000 claims description 2
- 230000001988 toxicity Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 230000019491 signal transduction Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 15
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022096329A JP2022133308A (ja) | 2016-04-15 | 2022-06-15 | キメラアロ抗原受容体ｔ細胞の組成物および方法 |
| JP2024107077A JP2024138334A (ja) | 2016-04-15 | 2024-07-03 | キメラアロ抗原受容体ｔ細胞の組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662322937P | 2016-04-15 | 2016-04-15 | |
| US62/322,937 | 2016-04-15 | ||
| PCT/US2017/027754 WO2017181101A1 (en) | 2016-04-15 | 2017-04-14 | Compositions and methods of chimeric alloantigen receptor t cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022096329A Division JP2022133308A (ja) | 2016-04-15 | 2022-06-15 | キメラアロ抗原受容体ｔ細胞の組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019513394A JP2019513394A (ja) | 2019-05-30 |
| JP2019513394A5 true JP2019513394A5 (enExample) | 2020-05-28 |
Family
ID=60042268
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018553980A Pending JP2019513394A (ja) | 2016-04-15 | 2017-04-14 | キメラアロ抗原受容体ｔ細胞の組成物および方法 |
| JP2022096329A Pending JP2022133308A (ja) | 2016-04-15 | 2022-06-15 | キメラアロ抗原受容体ｔ細胞の組成物および方法 |
| JP2024107077A Pending JP2024138334A (ja) | 2016-04-15 | 2024-07-03 | キメラアロ抗原受容体ｔ細胞の組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022096329A Pending JP2022133308A (ja) | 2016-04-15 | 2022-06-15 | キメラアロ抗原受容体ｔ細胞の組成物および方法 |
| JP2024107077A Pending JP2024138334A (ja) | 2016-04-15 | 2024-07-03 | キメラアロ抗原受容体ｔ細胞の組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20190153064A1 (enExample) |
| EP (1) | EP3443076A4 (enExample) |
| JP (3) | JP2019513394A (enExample) |
| KR (1) | KR20190003550A (enExample) |
| CN (1) | CN109328230A (enExample) |
| AU (2) | AU2017248817A1 (enExample) |
| CA (1) | CA3020599A1 (enExample) |
| MX (1) | MX2018012539A (enExample) |
| RU (1) | RU2018140056A (enExample) |
| WO (1) | WO2017181101A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210023170A1 (en) * | 2018-02-12 | 2021-01-28 | University Of Florida Research Foundation, Incorporated | Fviii chimeric antigen receptor tregs for tolerance induction in hemophilia a |
| SG11202101996QA (en) * | 2018-08-28 | 2021-03-30 | Immunotech Biopharm Co Ltd | Improved therapeutic t cell |
| US20220042039A1 (en) * | 2018-08-28 | 2022-02-10 | Pharos Vaccine Inc. | Improved lentiviral vector |
| CN110903399B (zh) * | 2018-09-17 | 2022-02-01 | 台湾中国医药大学附设医院 | 嵌合抗原受体、其核酸、表达质体、细胞、用途及组合物 |
| WO2020210768A1 (en) * | 2019-04-12 | 2020-10-15 | The Trustees Of The University Of Pennsylvania | Compositions and Methods Comprising a High Affinity Chimeric Antigen Receptor (CAR) with Cross-Reactivity to Clinically-Relevant EGFR Mutated Proteins |
| MX2021013949A (es) * | 2019-05-13 | 2022-01-04 | Univ Pennsylvania | Composiciones y metodos de celulas de receptor de autoanticuerpo quimerico del receptor de acetilcolina. |
| JOP20220099A1 (ar) * | 2019-11-05 | 2023-01-30 | Janssen Biotech Inc | علاج الورم النقوي المتعدد باستخدام خلايا car تائية تستهدف bcma |
| CN115516086A (zh) * | 2020-05-13 | 2022-12-23 | 南京传奇生物科技有限公司 | 类猿icp47及变体减少同种异体细胞宿主排斥的组合物及方法 |
| CN113646433B (zh) * | 2020-07-16 | 2022-10-11 | 苏州博腾生物制药有限公司 | 靶向抗TNF-α抗体的组合物和方法 |
| WO2022048621A1 (en) * | 2020-09-03 | 2022-03-10 | Porton Biologics Ltd | Compositions and methods to target anti-rh antibody |
| CN114369168B (zh) * | 2020-10-19 | 2024-08-30 | 南京卡提医学科技有限公司 | 包含dap12和共刺激信号分子信号域的嵌合受体及其使用方法 |
| WO2022083590A1 (zh) * | 2020-10-19 | 2022-04-28 | 南京卡提医学科技有限公司 | 包含dap12和共刺激信号分子信号域的嵌合受体及其使用方法 |
| CN116103239A (zh) * | 2021-11-11 | 2023-05-12 | 南京北恒生物科技有限公司 | 工程化免疫细胞及其用途 |
| EP4611775A1 (en) * | 2022-11-04 | 2025-09-10 | The Children's Hospital Of Philadelphia | Compositions and methods for b cell directed immunotherapies for anti-aav neutralizing alloantibodies |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US466A (en) | 1837-11-20 | Jordan l | ||
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| WO2001029058A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| AU4328801A (en) | 2000-02-24 | 2001-09-03 | Xcyte Therapies Inc | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| WO2005118788A2 (en) | 2004-05-27 | 2005-12-15 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
| WO2011023785A1 (en) * | 2009-08-27 | 2011-03-03 | Novo Nordisk A/S | Targeting tissue factor to activated platelets |
| EP2814846B1 (en) * | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| AU2013289984B2 (en) * | 2012-07-13 | 2018-03-08 | The Trustees Of The University Of Pennsylvania | Use of CART19 to deplete normal B cells to induce tolerance |
| WO2014160627A1 (en) * | 2013-03-25 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd276 polypeptides, proteins, and chimeric antigen receptors |
| DK3166968T3 (da) * | 2014-05-02 | 2021-12-06 | Univ Pennsylvania | Sammensætninger og fremgangsmåder til kimæriske autoantistofreceptor-T-celler |
| WO2015171863A1 (en) * | 2014-05-08 | 2015-11-12 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | USING B-CELL-TARGETING ANTIGEN IgG FUSION AS TOLEROGENIC PROTEIN THERAPY FOR TREATING ADVERSE IMMUNE RESPONSES |
| EP3384013A4 (en) * | 2015-12-04 | 2019-07-10 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | ANTIGEN-SPECIFIC T CELLS FOR INDUCING IMMUNOTOLERANCE |
-
2017
- 2017-04-14 US US16/093,539 patent/US20190153064A1/en not_active Abandoned
- 2017-04-14 AU AU2017248817A patent/AU2017248817A1/en not_active Abandoned
- 2017-04-14 MX MX2018012539A patent/MX2018012539A/es unknown
- 2017-04-14 WO PCT/US2017/027754 patent/WO2017181101A1/en not_active Ceased
- 2017-04-14 KR KR1020187032117A patent/KR20190003550A/ko not_active Ceased
- 2017-04-14 CA CA3020599A patent/CA3020599A1/en active Pending
- 2017-04-14 RU RU2018140056A patent/RU2018140056A/ru unknown
- 2017-04-14 JP JP2018553980A patent/JP2019513394A/ja active Pending
- 2017-04-14 EP EP17783306.8A patent/EP3443076A4/en active Pending
- 2017-04-14 CN CN201780036162.2A patent/CN109328230A/zh active Pending
-
2021
- 2021-08-23 US US17/409,354 patent/US20220220188A1/en not_active Abandoned
-
2022
- 2022-06-15 JP JP2022096329A patent/JP2022133308A/ja active Pending
-
2023
- 2023-09-01 AU AU2023222993A patent/AU2023222993A1/en active Pending
-
2024
- 2024-07-03 JP JP2024107077A patent/JP2024138334A/ja active Pending
-
2025
- 2025-10-06 US US19/350,593 patent/US20260028386A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019513394A5 (enExample) | ||
| JP7505885B2 (ja) | 腫瘍微小環境を標的にするキメラ抗原受容体ｔ細胞 | |
| JP2018508219A5 (enExample) | ||
| JP7770188B2 (ja) | 養子細胞療法のための標的共刺激を提供する受容体 | |
| JP7068459B2 (ja) | Ｎｙｅｓｏ ｔｃｒ | |
| RU2018140056A (ru) | Композиции и способы с использованием т-клеток с химерным рецептором аллоантигена | |
| JP2020511136A5 (enExample) | ||
| JP7717439B2 (ja) | 修飾されたｔ細胞及びその使用方法 | |
| JP2020114264A5 (enExample) | ||
| JP2025032089A (ja) | 腫瘍微小環境を標的とするキメラ抗原受容体 | |
| JP2024156654A (ja) | 新規操作ｔ細胞受容体およびそれを使用した免疫療法 | |
| JP2019122380A (ja) | Ｃｌｄ１８ａ２標的免疫エフェクター細胞及びその調製方法と使用 | |
| JP2017537919A5 (enExample) | ||
| JP2018029594A5 (enExample) | ||
| JP2016520074A5 (enExample) | ||
| CN108137670A (zh) | Ny-eso-1特异性tcr及其使用方法 | |
| JP2017519494A (ja) | Ｏｘ４０ｌ融合タンパク質およびその使用 | |
| KR20170101206A (ko) | 조작된 감마 델타 t 세포 | |
| RU2017133637A (ru) | Иммуномодулирующие слитые белки и пути их применения | |
| JP2019530431A5 (enExample) | ||
| JP2015513920A5 (enExample) | ||
| EP3568466A1 (en) | Targeted t cells with cytotoxicity toward immunosuppressive cells | |
| JP2025107358A (ja) | 細胞 | |
| JP2022527813A (ja) | Ｍａｇｅａ１特異的ｔ細胞受容体およびその使用 | |
| US20220064256A1 (en) | Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies |